Literature DB >> 20331500

Brainstem hyperperfusion syndrome after intravenous thrombolysis: a case report.

Chi-Ieong Lau1, Li-Ming Lien, Wei-Hung Chen.   

Abstract

BACKGROUND AND
PURPOSE: Recombinant tissue plasminogen activator (rtPA)-associated hyperperfusion syndrome in brainstem after acute stroke has not yet been reported. The current report demonstrates that rtPA-associated hyperperfusion syndrome can be a cause of clinical deterioration following improvement (DFI) after rtPA in acute stroke.
METHODS: We observed a transient DFI in a 59-year-old man with acute ischemic stroke who received rtPA. The phenomenon was assessed by magnetic resonance imaging (MRI) with diffusion-weighted image (DWI) and a series of transcranial Doppler scan evaluating changes in the basilar arterial flow.
RESULTS: We demonstrated a reversible hyperintensity at pons on DWI as well as a transient increase in basilar arterial flow on Doppler scan suggesting the occurrence of vasogenic edema and hyperperfusion at brainstem.
CONCLUSIONS: rtPA-associated hyperperfusion can occur at brainstem causing transient neurological deficits. It can be a cause of DFI in addition to reocclusion after recanalization.
© 2010 by the American Society of Neuroimaging.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20331500     DOI: 10.1111/j.1552-6569.2010.00469.x

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  2 in total

1.  Imaging Evidence for Cerebral Hyperperfusion Syndrome after Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke.

Authors:  Yi Zhang; Abhay Kumar; John B Tezel; Yihua Zhou
Journal:  Case Rep Neurol Med       Date:  2016-05-03

2.  Early Neurological Deterioration after Recanalization Treatment in Patients with Acute Ischemic Stroke: A Retrospective Study.

Authors:  Ying-Bo Zhang; Ying-Ying Su; Yan-Bo He; Yi-Fei Liu; Gang Liu; Lin-Lin Fan
Journal:  Chin Med J (Engl)       Date:  2018-01-20       Impact factor: 2.628

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.